

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
DOCKET NO. PENT-298-EXT

U.S. Patent No. : 5,877,298

Inventors : Fahim, et al.

Assignee : Aventis Pasteur Limited

Issued : March 2, 1999

**For : ACELLULAR PERTUSSIS VACCINES AND
METHODS OF PREPARATION THEREOF**


Mail Stop Hatch-Waxman PTE
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Submitted via facsimile to 571-273-7755

**SUBMISSION RELATED TO APPLICATION FOR EXTENSION OF
PATENT TERM UNDER 35 U.S.C. § 156**

Pursuant to 37 C.F.R. § 1.730, please find attached a substitute signature page for the application for extension of patent term under 35 U.S.C. 1.56 filed Aug. 15, 2008 for the above-described patent. The Office is encouraged to contact the undersigned with any comments and / or questions.

Respectfully submitted,

January 2, 2009



Patrick J. Malloran
Reg. No. 41,053

(15) The name, address, and telephone number of the person to whom inquiries and correspondence relating to the application for patent term extension are to be directed.

Reza Yacoob
Director, Intellectual Property
Sanofi Pasteur Limited
1755 Steeles Ave.
Ontario, Toronto, Canada

Respectfully submitted,

By: Patrick J. Halloran



REG. NO. 41,053

Date: August 15, 2008

Exhibits

- A: Certificate of Amendment of Certificate of Incorporation of Aventis Pasteur Limited showing name change to Sanofi Pasteur Limited
- B: Certificate of Amendment of Certificate of Incorporation of Connaught Laboratories Limited showing name change to Aventis Pasteur Limited
- C: Assignment of U.S. Pat. No. 5,877,298 from each inventor to Aventis Pasteur Limited
- D: Approved Packaging Insert for PENTACEL®
- E: FDA approval letter for PENTACEL®
- F: U.S. Patent No. 5,877,298
- G: Certificate of Correction dated October 26, 1999
- H: Copy of Maintenance Fee Statement for U.S. Pat. No. 5,877,298
- I: Chart listing the start date and end date of each PENTACEL® clinical trial